EGFR and lung adenocarcinoma: More than half of lung adenocarcinoma patients in Japan harbor EGFR mutations [22], and resistance to EGFR tyrosine kinase inhibitors (TKIs) and relapse are associated with tumor clones harboring secondary-resistant mutations, which become more common during and after treatment.